[Focus on cystic fibrosis]
Isabelle Sermet-Gaudelus1, Marlène Clairicia Pierre-Joseph1, Aline Lustre1
1CRCM pédiatrie, Hôpital universitaire Necker-Enfants malades, 149, rue de Sèvres, 75015 Paris, France.
Revue De L'Infirmiere
|March 10, 2020
Insights
Cystic fibrosis, a genetic disorder primarily affecting the lungs, has seen significantly reduced mortality rates. Improved treatments have increased the life expectancy for individuals with cystic fibrosis to over 50 years at birth.
Area of Science:
- Medical Genetics
- Pulmonology
- Clinical Medicine
Background:
- Cystic fibrosis (CF) is an inherited disorder primarily impacting the respiratory system.
- Historically, CF presented a grave prognosis with limited survival.
- Advances in medical care have transformed patient outcomes.
Purpose of the Study:
- To review the current status of cystic fibrosis management.
- To highlight the impact of therapeutic advancements on patient longevity.
- To provide an overview of the current life expectancy in CF patients.
Main Methods:
- Literature review of clinical studies and treatment guidelines.
- Analysis of epidemiological data on cystic fibrosis mortality and survival rates.
- Synthesis of current therapeutic strategies for CF symptom management.
Main Results:
- Significant reduction in mortality rates for cystic fibrosis patients.
- Current life expectancy at birth for individuals with CF exceeds 50 years.
- Improved management of respiratory and other CF-related symptoms is key.
Conclusions:
- Modern therapeutic approaches have dramatically improved survival in cystic fibrosis.
- Continued research and treatment optimization are essential for further progress.
- Cystic fibrosis is now a manageable chronic condition for many, with extended life expectancies.
Abstract:
Cystic fibrosis is a genetic disease whose most common symptoms are of respiratory nature. Mortality has been drastically reduced through better treatment of the various symptoms. Life expectancy at birth is currently over 50 years.
Keywords:
cystic fibrosismanagementmucoviscidosepathophysiologyphysiopathologieprise en chargesymptomsymptômeMore Related Videos
Related Concept Videos
01:24Cystic Fibrosis: Management
387
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
387
01:23Cystic Fibrosis: Pathogenesis
647
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
647
01:22Chronic Obstructive Pulmonary Disease
2.1K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.1K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.0K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.0K
01:20COPD: Pathogenesis and Clinical Features
1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.4K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.4K